Want to see CLSDQ full AI Analyst Report?
CLSDQ Stock Chart & Stats
$0.82
<$0.01(0.46%)
At close: 4:00 PM EST
$0.82
<$0.01(0.46%)
Day’s Range― - ―
52-Week Range$0.01 - $13.49
Previous CloseN/A
VolumeN/A
Average Volume (3M)64.39K
Market Cap
$1.31M
Enterprise Value$55.39M
Total Cash (Recent Filing)$6.80M
Total Debt (Recent Filing)$61.61M
Price to Earnings (P/E)―
Beta0.09
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,233,981
10 Day Avg. Volume36,098
30 Day Avg. Volume64,393
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-1.80
Price to Sales (P/S)42.14
P/FCF Ratio-2.73
Enterprise Value/Market Cap42.28
Enterprise Value/Revenue16.64
Enterprise Value/Gross Profit19.45
Enterprise Value/Ebitda-3.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery TechnologyOwnership of a specialized SCS Microinjector is a durable competitive asset in posterior-eye therapeutics. It creates differentiation, supports licensing or partnership revenue, and can sustain long-term commercial and collaboration opportunities even if clinical timelines slip.
High Gross MarginsAn ~86% gross margin indicates the underlying delivery technology or products have low direct costs relative to revenue. If commercialized, such margins provide operating leverage, enabling profitability once fixed R&D and SG&A scale down or are restructured over the medium term.
Low Reported DebtMinimal formal debt reduces interest and covenant burdens and can simplify restructuring outcomes. Lower secured liabilities may improve recoveries for stakeholders and provide strategic flexibility during turnaround or a sale process compared with heavily leveraged peers.
Bears Say
Chapter 11 Bankruptcy And Asset-sale ProcessA Chapter 11 filing and active asset-sale process fundamentally alter the company's ability to execute long-term plans. Restructuring and potential asset dispositions threaten continuity, reduce value capture for equity holders, and likely end independent commercialization of current programs.
Negative Shareholders' EquityPersistently negative equity reflects cumulative operating losses and capital erosion, constraining the firm's ability to raise traditional equity and signaling solvency issues. This structural capital weakness limits strategic options and increases priority claims from creditors in any restructuring.
Sustained Cash Burn And Weak Cash GenerationConsistent, large negative operating and free cash flows indicate the business cannot self-fund R&D or operations. Over months this drives reliance on external financing or asset sales, elevates bankruptcy risk, and undermines the firm's ability to support long-term development and commercialization.
Clearside Biomedical News
CLSDQ FAQ
What was Clearside Biomedical’s price range in the past 12 months?
Clearside Biomedical lowest stock price was $0.01 and its highest was $13.49 in the past 12 months.
What is Clearside Biomedical’s market cap?
Clearside Biomedical’s market cap is $1.31M.
When is Clearside Biomedical’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Clearside Biomedical’s earnings last quarter?
Currently, no data Available
Is Clearside Biomedical overvalued?
According to Wall Street analysts Clearside Biomedical’s price is currently Overvalued.
Does Clearside Biomedical pay dividends?
Clearside Biomedical does not currently pay dividends.
What is Clearside Biomedical’s EPS estimate?
Clearside Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clearside Biomedical have?
Clearside Biomedical has 5,233,981 shares outstanding.
What happened to Clearside Biomedical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Clearside Biomedical?
Currently, no hedge funds are holding shares in CLSDQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clearside Biomedical
Clearside Biomedical, Inc. operates as a biopharmaceutical company, specializing in novel approaches to administer therapies to the posterior region of the eye via the suprachoroidal space. Its market-approved product, XIPERE, is an injectable suspension containing triamcinolone acetonide, utilized to manage macular edema associated with uveitis. Additionally, the firm is progressing CLS-AX, an axitinib injectable suspension intended for suprachoroidal injection, having concluded its Phase 2 clinical trial for the treatment of wet age-related macular degeneration (AMD). Strategic collaborations are in place with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Founded in 2011 and headquartered in Alpharetta, Georgia, Clearside Biomedical regrettably initiated Chapter 11 reorganization proceedings by filing a voluntary petition with the U.S. Bankruptcy Court for the District of Delaware on November 23, 2025.
Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Aptevo Therapeutics
―
Processa Pharmaceuticals
―
Rallybio
―
Cingulate Inc
―
Ownership Overview
―
Insiders
0.10% Mutual Funds
0.52% Other Institutional Investors
99.38% Public Companies and
Individual Investors